To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae rolled up several ...

Operator: Good afternoon, and welcome to the Invitae Third Quarter 2023 Financial Results Conference Call. My name is Carla and I will be your operator for today's call.

NEW YORK, Feb 15 (Reuters) - Invitae Corp NVTAQ.PK received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a buyer and exit from ...

Fintel reports that Sumitomo Mitsui Trust Holdings has filed a 13G/A form with the SEC disclosing ownership of 17.26MM shares of Invitae Corp (NVTA). This represents 7.1% of the company. In their ...

Invitae Corp NVTA shares are taking off in Thursday's after-hours session after Ark Invest's Cathie Wood discussed the name on CNBC's "Closing Bell: Overtime." "We do believe the breakthroughs that we ...

Invitae Corp. continued its aggressive cost-cutting initiative with the sale of its reproductive health assets to Natera Inc. for $10 million in upfront cash and an additional $42.5 million in ...

Raising capital to fund the company’s current operations will remain difficult, analyst says. Invitae is likely to emerge as 'a lower-growth player in competitive end markets.' Despite having a ...

* CombiMatrix Corp - for services provided by Invitae, CombiMatrix Molecular Diagnostics will pay Invitae a $200 fee for each test that Invitae markets * CombiMatrix Corp - ‍under terms of marketing ...

Invitae Corp. has entered into a partnership with Bridgebio Pharma Inc. to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on ...

Labcorp beats Q2 profit and revenue estimates on demand for health tests Labcorp beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic ...